Sinovac Biotech (SVA +3.9%) says a new drug application for its proprietary EV71 vaccine has been filed and accepted by the Beijing Drug Administration. SVA completed the Phase III clinical trials for the vaccine in March, and top-line data showed approximately a 95% efficacy rate against HFMD caused by enterovirus 71. The Administration plans to conduct an on-site inspection and will submit its opinion to China's Food and Drug Administration for further review and evaluation.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs